Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michael Moore

Orthopaedic Surgery of the Spine Greensboro, NC Medical Doctor

NPI 1154856920 CMS profile 11306051

1211 Virginia St, Greensboro, NC 27401

Open in the dashboard

General payments

$83,363

35 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Moore of Greensboro, NC is reported in the CMS Open Payments database as having received $83,363 across 35 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $233 2
2024 General $1,609 5
2023 General $5,025 23
2022 General $75,296 4
2021 General $1,200 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Moore
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Michael Moore were reported at $233. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Michael Moore Orthopaedic Surgery of the Spine median Middle half National median
2019 $0 $2,106 $337–$18,608 $163
2020 $0 $1,213 $156–$15,082 $114
2021 $1,200 $1,834 $271–$15,617 $132
2022 $75,296 $2,015 $320–$17,036 $149
2023 $5,025 $1,925 $336–$14,599 $160
2024 $1,609 $2,110 $341–$12,483 $164
2025 $233 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $75,131 4 payments
  2. Globus Medical, Inc. $5,859 16 payments
  3. Legacy Ortho LLC $1,200 1 payment
  4. Smith+Nephew, Inc. $390 4 payments
  5. Stryker Corporation $296 3 payments
  6. NuVasive, Inc. $272 4 payments
  7. DePuy Synthes Sales Inc. $196 2 payments
  8. Dexcom, Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Grant $75,000 1 payment
  2. Travel and Lodging $5,785 15 payments
  3. Food and Beverage $1,379 18 payments
  4. Education $1,200 1 payment
Products named General payments · program years 2021–2025
  1. CD HORIZON SPINAL SYSTEM $75,000 1 payment
  2. ELSA, ELSA AL/ATP $4,045 11 payments
  3. XLIF $1,647 6 payments
  4. ExcelsiusGPS Robotic Navigation System $364 2 payments
  5. TRIGEN INTERTAN $288 3 payments
  6. GAMMA $276 2 payments
  7. AXSOS $195 1 payment
  8. HOFFMANN $195 1 payment
  9. EVOS $187 2 payments
  10. Vivigen MIS Delivery System $119 1 payment
  11. Other $955 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

955

Median for Orthopedic Surgery: 203

Drug cost

$8,473

Median for Orthopedic Surgery: $1,433

Branded share of claims

5%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 139 $1,887
Gabapentin Generic 107 $1,200
Methocarbamol Generic 128 $957
Oxycodone Hcl Generic 131 $851
Naproxen Generic 29 $803
Methylprednisolone Generic 60 $434
Tizanidine Hcl Generic 51 $432
Diclofenac Sodium Generic 28 $402
Tramadol Hcl Generic 85 $265
Celecoxib Generic 14 $250

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$38,777

Medicare's payments for the services billed

Medicare patients

106

Average age 75

Services billed

452

64 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 40%
Depression 38%
Ischemic heart disease 30%
Osteoporosis 30%
Chronic kidney disease 29%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

35 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record